S100A9 and lung adenocarcinoma: The percentage of blood S100A9+ MDSC in the EGFR-mutated lung adenocarcinoma patients (17.7 ± 10.6, n = 58) was higher than that of healthy donors (7.5 ± 1.8, n = 7, p = 0.008).